First Targeted Therapy for Pancreatic Cancer Approved | Augusta Georgia News

FDA just approved a breakthrough pill for advanced pancreatic cancer — daraxonrasib, branded as Rasonque — offering hope where there was once little. Designed for patients who’ve already tried or can’t undergo chemo, this targeted therapy attacks mutated RAS proteins, the root cause of most pancreatic tumors. In trials, it doubled median survival to 13 months versus 6 with chemo and slashed death risk by 60%. Though side effects like rash and nausea occur, over 2,000 patients have already accessed it through an expanded program. Even Senator Ben Sasse, battling Stage Four, credits it with shrinking his tumors — proving this isn’t just science fiction, but real progress in a disease long considered untouchable. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/abd9889f4fff550c